Invited Speakers

MORE INFO

COMING SOON

DENISA

WAGNER

DENISA WAGNER

Denisa Wagner grew up in Prague, Czechoslovakia. She studied Biochemistry at the University of Geneva, Switzerland. Then she moved to the United States, where she obtained a Ph.D. in Biology from the Massachusetts Institute of Technology. She is currently the Edwin Cohn Professor of Pediatrics in the Program in Cellular and Molecular Medicine and the Division of Hematology/Oncology at Boston Children’s Hospital.

Her expertise lies in the fields of vascular biology, inflammation and thrombosis. For many years, her laboratory’s research has focused on adhesion molecules. Specifically, the regulation of their expression and function in normal physiology, and in pathological situations. Her lab has engineered mice lacking platelet, endothelial, or leukocyte adhesion molecules, such as von Willebrand factor and P-selectin, and has studied these mice in disease models. One of the lab’s main interests is the interplay of inflammation and thrombosis. Recently, they have begun to explore the impact of neutrophil extracellular traps (NETs), which are chromatin coated with enzymes that are actively released from stimulated neutrophils.

Dr. Wagner’s group has found both an important prothrombotic role of NETs, as well as detrimental/toxic effects of NETs formed during injury and after myocardial infarction. Most recently, they observed that NET formation is enhanced by cancer, diabetes, and the aging process; conditions that promote inflammation and thrombosis. Dr. Wagner is the recipient of the Robert P. Grant Medal from the ISTH, an Outstanding Investigator Award by the NHLBI, and was named Distinguished Scientist by the AHA in 2017.

FRITS

ROSENDAAL

FRITS ROSENDAAL

Frits Rosendaal is professor of Clinical Epidemiology at the Leiden University Medical Center. He has a long standing track record in research in thrombosis and haemostasis, with many publications in leading biomedical journals. He designed several studies, such as LETS and MEGA,  that were instrumental in the identification of a series of risk factors for thrombosis, which ranged from genetic factors to environmental ones, particularly related to drug safety, such as specific brands of oral contraceptives. In the field of anticoagulant treatment he developed the method used to estimate the time in therapeutic range (TTR). In the field of haemophilia, he oversees the Haemophilia in the Netherlands national projects, and is involved in studies of inhibitor development, again in the context of drug safety.

He is recipient of the Spinoza award, which is the highest scientific prize in The Netherlands, is elected fellow of the Royal Academy of Arts and Sciences in the Netherlands, and of the German Academy Leopoldina, and received an honorary doctorate from the University of Paris Descartes. He was chairman of the Netherlands Society on Thrombosis and Haemostasis and of the Council of the International Society on Thrombosis and Haemostasis. He is Editor in Chief of the journal of Thrombosis and Haemostasis. He is member of the Council of the Committee on Publication Ethics (COPE), and chairman of the Leiden University Committee on Scientific Integrity. He founded the ECTH.

ANDREAS

GREINACHER

ANDREAS GREINACHER

Andreas Greinacher received his M.D. from the Universities of Aachen and Würzburg, Germany. He specialized for transfusion medicine, immuno hematology and clinical immunology at the University Giessen, Germany. Since 1994 he is head of the department of transfusion medicine at the Universitätsmedizin Greifswald were he helds a full professorship in transfusion medicine.

His major areas of research interest are hereditary and immune mediated thrombocytopenias, especially heparin-induced thrombocytopenia and the application of nanotechnologies and biophysical methods to understand the molecular mechanisms of antigenicity of endogenous proteins. He has published more than 400 papers on these topics and contributed to many textbooks in thrombosis and hemostasis. He is a member of the platelet immunology SSC, the platelet physiology SSC, and the perioperative hemostasis management SSC, and served as a member of the ISTH Council (2010-2016).

PETER

LENTING

PETER LENTING

Peter Lenting obtained his PhD with honours at the medical faculty of the University of Amsterdam, the Netherlands in 1996. He was appointed associate-professor of haematology at the University Medical Center in Utrecht, the Netherlands in 2000. Between 2007 and 2009, he held a position of Director of Protein & Antibody Discovery at Crucell Holland (Leiden, the Netherlands). In March 2009, he joined Inserm as Director of Research.

His research activities are mainly focussed on the Factor VIII/von Willebrand factor (FVIII/VWF) complex and the related disorders haemophilia A and von Willebrand disease. He was elected member of the council of the International Society of Thrombosis and Haemostasis (ISTH) in 2012, and chairs the ISTH-WHO-liaison committee. He is also an elected member of the council of the French Group for Thrombosis & Haemostasis (2017), and is member of the Scientific advisory board of the French Association for Haemophilia patients. In 2009, Dr. Lenting received the Prix Danièle Hermann (Foundation for Cardio-vascular Research, Institut de France) for his research activities.

GUY

MEYER

GUY MEYER

Guy Meyer is Professor of Respiratory Medicine at Paris Descartes University and chief of the department of respiratory and intensive care medicine at Hôpital Europeen Georges Pompidou in Paris. He is the chair of INNOVTE, a large network of clinical sites and research units cooperating in clinical trials on venous thromboembolism in France.

Dr Meyer received his MD degree at Paris VII University in 1986 and trained in respiratory medicine and intensive Care at Hôpital Laennec in Paris. He received training in basic science research at University Paris VII and INSERM under the direction of A Tedgui.

Dr Meyer is involved in clinical research on the diagnosis, epidemiology and treatment of pulmonary embolism. He has published more than 150 articles indexed in pubmed. He has been involved in many studies on pulmonary embolism published in major journals. The relationship of thromboembolism and cancer is one of his main fields of interest. He is the principal investigator of the TILT trial, a randomized trial to evaluate the effect of Low Molecular Weight Heparin on the survival of patients with localized lung cancer and the PROVE trial, a randomized trial assessing the role of Low Molecular Weight Heparin for the long-term prophylaxis of venous thromboembolism in patients with advanced lung cancer.

CARMEN

ESCURIOLA-ETTINGSHAUSEN

CARMEN ESCURIOLA-ETTINGSHAUSEN

Dr Carmen Escuriola Ettingshausen is the Director of the Haemophilia Centre Rhein Main – HZRM, Frankfurt-Mörfelden, Germany.
She graduated in medicine at the Johann Wolfgang Goethe-University in Frankfurt from 1985 to 1992. After that, she became resident at the comprehensive care centre for Thrombosis and Haemostasis of the Children´s Hospital at University Hospital of Frankfurt in the department of Paediatrics until 1996, and obtained the Doctor title in 1995. She performed specialist´s training in Paediatrics at the University Hospital of Frankfurt from 1996 until 2000, and since then she was a staff member at the comprehensive care centre for Thrombosis and Haemostasis of the University Hospital of Frankfurt, department of Paediatrics until 2012. In 2012 she founded the Haemophilia Centre Rhein-Main, Frankfurt-Mörfelden.

Dr Escuriola-Ettingshausen’s clinical interests include haemorrhagic disorders with a focus on haemophilias, thrombosis, congenital immunodeficiencies, and hereditary angioedema in both pediatric and adult patients.

Her research interests are Haemorrhagic disorders, particularly in treatment of haemophiliacs and haemophiliacs with inhibitors. Moreover, she is member of the German, Swiss and Austrian Society For Thrombosis and Haemostasis Research (GTH), International Society for Thrombosis and Haemostasis (ISTH) and the International Prophylaxis Study Group (IPSG).

 

STEFFEN

MASSBERG

STEFFEN MASSBERG

Steffen Massberg is Professor of Cardiology and Director of the Department of Cardiology at the University Clinic Munich, Ludwig-Maximilians University in Germany.

His basic-science research topics include stem-cell biology, platelet biology, mechanisms of arterial and venous thrombosis, immune-cell migration, immune-cell/coagulation crosstalk and bio-imaging (including 2-photon microscopy). He has written over 135 articles published in national and international peer-reviewed journals, including Blood, Nature Reviews Immunology, The Journal of Experimental Medicine and Circulation.

Professor Massberg is the co-ordinator and lead scientist of the European FP7 project PRESTIGE, the co-speaker and principal investigator of the DFG Collaborative Research Unit (SFB) 914 and the principal investigator of the DFG-Research Unit (FOR) 923. He has received many prizes for his work, the most recent being the 2011 Martin Villar Haemostasis Award (together with Dr Bernd Engelmann) and the 2012 Basic Science Award from the German Society of Cardiology (DGK).

 

CHRISTOPHE

DUBOIS

CHRISTOPHE DUBOIS

Christophe Dubois grew up in Perpignan, South of France. He studied biotechnology and cell biology at the university of Marseille, France. During his PhD he worked at Hoffmann-La Roche, Basel, Switzerland in the Dr Beat Steiner’s group.  He obtained his PhD at the university of Marseille in 2003. Then he moved to the United States in the Dr. Barbara and Bruce Furie’s lab at Boston, MA. Back to France, between 2006 and 2015 he held a position of Associate Professor at the Faculty of Medicine in Marseille. In 2015, he joined the Faculty of Pharmacy, Aix Marseille University, as Professor in Cell Biology.

His research activities are mainly focused on the mechanisms involved in thrombus formation and in thrombosis associated with cancer. He was elected member of the INSERM Scientific specialized committee (2009-2012), member of the council of the French Group on thrombosis and Cancer (2011-2016) and member of the council of the French Group for Thrombosis & Haemostasis (2013). Since 2017, he is co-chair of the Scientific and Standardization Committee on Hemostasis and malignancy from the ISTH.

 

MARCO

CATTANEO

MARCO CATTANEO

Marco Cattaneo is Professor of Internal Medicine and Director of the Unit of Internal Medicine at Ospedale San Paolo, Università degli Studi di Milano, Italy. After gaining his MD at the Universirtà degli Studi di Milano, he specialized in Clinical and Laboratory Haematology at the Università degli Studi di Pavia, followed by a Residency at the A. Bianchi Bonomi Haemophilia and Thrombosis Centre and Institute of Internal Medicine at the Ospedale Maggiore, Università degli Studi di Milano. He has been Post-Doctoral Fellow at McMaster University, Hamilton, Ontario and Guest or Visiting Scientist at McMaster University, Hamilton, Ontario, Temple University, Philadelphia and The Scripps Research Institute, La Jolla, California.

His main research interests focus on pathophysiology of primary haemostasis, pharmacology of antiplatelet agents and the role of homocysteine in thrombotic disease.

Author of more than 300 original articles published in peer-reviewed scientific journals. In 2001 he was awarded the International Society on Thrombosis and Haemostasis (ISTH) 10th Biennial Award for Contributions to Haemostasis and Thrombosis. He has been Editor of Thrombosis Research and on the Editorial Board/Advisory Board for a number of other high-tier journals, including Jornal of Thrombosis and Haemostasis, Haematologica, Platelets, Thrombosis and Haemostasis and Arteriosclerosis, Thrombosis and Vascular Biology. He was Chair of the Working Party on Platelet Aggregation, and Chair of the Scientific Subcommittee on Platelet Physiology, Scientific and Standardization Committee, ISTH. He was a member of the Council of the ISTH from 2010 through 2016.

DEIRDRE

LANE

DEIRDRE LANE

Dr Lane is a Senior Lecturer in Cardiovascular Health at the University of Birmingham in the UK and Adjunct Professor of Cardiovascular Health at Aalborg University, Denmark. Atrial fibrillation is her main research interest focused on bleeding and stroke risk stratification and patient-centred research. She is a co-author of both the CHA2DS2-VASc stroke risk stratification score and the HAS-BLED bleeding risk score. Her other main research interest is how AF affects quality of life and psychological well-being, patient education, and patients’ perceptions of AF and medication adherence. She was the Chair for a recent European Heart Rhythm Association (EHRA) position document on ‘Cardiac tachyarrhythmias and patient values and preferences for their management’ and is a member of American College of Chest Physicians guidelines on antithrombotic therapy in AF patients. She has published her work widely in journals such as Stroke,

Chest, JACC, Thrombosis and Haemostasis, and BMJ.

SUZANNE

CANNEGIETER

SUZANNE CANNEGIETER

Suzanne Cannegieter is a professor of Clinical Epidemiology at the Leiden University Medical Center in the Netherlands. She focuses her research on venous thrombosis, with a particular interest in its aetiology, as well as in establishing optimal prevention and therapy. A few examples of topics include the relation between venous thrombosis and surgery, cancer, cardiovascular disease, air travel, female risk factors, endocrine hormones, infection and risk factors for recurrent thrombosis.

Suzanne Cannegieter is a member of the Education Committee of the Council of the International Society on Thrombosis and Haemostasis (ISTH) and co-chair of the ISTH Scientific Subcommittee on Predictive and Diagnostic Variables. She was board member of the Netherlands Society for Thrombosis and Haemostasis (NVTH) and was a member of the Local Organizing Committee (Education) for the 24th Congress of ISTH, held in Amsterdam 2013. She is a member of the Scientific Advisory Board of the Dutch Thrombosis Foundation. She is Associate Editor for ‘Research and Practice in Thrombosis and Haemostasis’ and member of the Editorial Board for the Journal of Thrombosis and Haemostasis and PLoS Medicine.

CRISTINA

NOVEMBRINO

CRISTINA NOVEMBRINO

Cristina Novembrino has a PHD in Biochemistry from the University of Milan. From 1998 up to now she participates in national and international congresses with poster and oral communications. She is first author and co-author of more than 40 scientific publications on international journals.

MARIBEL

MIRABET

MARIBEL MIRABET

Maribel Mirabet graduated in Chemistry (Biochemistry specialty) in 1992 and obtained her PhD from the University of Barcelona in 1998. From 1999 to 2007 she worked as Postdoctoral Fellow and as Researcher at the Research Institute of the Hospital Vall d’Hebron in Barcelona (Spain), participating in projects investigating the mechanisms and consequences of platelet activation during acute myocardial infarction. From 2007 until 2010, she worked for the pharmaceutical industry at the Development Department of Ipsen Pharma (Sant Feliu de Llobregat, Spain), involved in the development of assays for immunogenicity studies. From 2010 until now, she is working as a Senior Scientist at the Assay Development Department of Biokit R&D (Lliçà d’Amunt, Spain), researching and developing chemiluminescent immunoassays. Her work at Biokit has been primarily focused on the development of a rapid and fully automated immunoassay to quantify ADAMTS13 activity in plasma.

YVES

GRUEL

YVES GRUEL

Yves Gruel is MD and Professor of Hematology in the University François Rabelais (Tours-France) since 1993. He is the head of the department of Hemostasis in Trousseau Hospital (Tours) with a bio-clinical activity focusing on congenital and acquired bleeding and thrombotic disorders. He is coordinating the medical activities of the Haemophilia Care Centre of the “Région Centre” in France.
He has contributed to several pivotal studies on the physiopathology, diagnosis and treatment of Heparin-Induced Thrombocytopenia.
He is member of American Society of Hematology (ASH); International Society of Haemostasis and Thrombosis (ISTH) and has been Chairman of the ISTH subcommittee “Platelet Immunology” in 2011-14. He is also President of the French study Group on Hemostasis and Thrombosis (Groupe Français d’Etudes sur l’Hémostase et la Thrombose; GFHT) since 2013.
He is co-author of more than 180 indexed articles, mostly on HIT and published in Blood, Circulation, Journal of Thrombosis and Haemostasis and Thrombosis and Haemostasis.

BRETT

MONIA

BRETT MONIA

Dr. Monia is a founding member of Ionis and is the Chief Operating Officer and Senior Vice President of Antisense Drug Discovery and Translational Medicine. He is also the Franchise Leader for Programs in Oncology and Rare Diseases at Ionis. As head of Drug Discovery and Translational Medicine, Dr. Monia is responsible for establishing strategic directions for preclinical drug discovery research focused on RNA-directed therapeutic platforms, establishment and supervision of early clinical development strategies, and coordinating research activities with clinical investigators, consultants, and with corporate partners. His contributions include research into the medicinal chemistry and mechanisms of action of oligonucleotide-based drugs in cell culture and in animals, and in the establishment of numerous preclinical and clinical programs, many of which have resulted in clinical proof of concept across a broad range of therapeutic areas, including oncology, cardio-metabolic diseases, inflammation, respiratory diseases, neurodegenerative diseases, and rare diseases.  Programs under Dr. Monia’s direct supervision have resulted in the clinical development of more than forty antisense-based drugs to date, resulting in multiple market authorization approvals.

Dr. Monia has also served as President of the Oligonucleotide Therapeutics Society (OTS), and currently serves on the Board of Directors for Dynacure Therapeutics and as an adjunct professor of Biology at San Diego State University.

Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State University, in Pomona, New Jersey.

MICHAEL A.

GROSSO

 

MICHAEL A. GROSSO

As Head, Clinical Development for Specialty Medicine at Daiichi-Sankyo, Michael oversees the ongoing global clinical development of edoxaban, a novel factor FXa inhibitor, as well as several novel thrombosis and cardiovascular, renal, ophthalmologic, pain, cell therapy medical products in pipeline development. He has extensive experience in all aspects of clinical development including regulatory affairs with several successful global NDA filings. Prior to joining Daiichi-Sankyo, Michael spent 3 years at Sanofi Aventis as Medical Director, Cardio-Thrombosis where he managed the cardiovascular and thrombosis clinical trials in North America, including with novel FXa inhibitors, low molecular weight heparins, anti-platelet and anti-arrhythmic drugs. Before joining the pharmaceutical industry, Michael served as Senior Research Investigator for the heart failure research group at University of Pennsylvania. As a Board-certified academic cardiothoracic surgeon, he has over 15 years of past clinical experience while also serving as a primary investigator in basic science and clinical research. He has authored or co-authored over 100 abstracts, manuscripts and book chapters and served as a consultant to the pharmaceutical industry for many years prior to joining the industry.

BENJAMIN

KIM

BENJAMIN KIM

Dr. Kim is a Senior Medical Director and the Clinical Development Team Lead for valoctocogene roxaparvovec (BMN 270).  He joined BioMarin in June 2017 after serving as an Associate Medical Director at Roche, where he was the medical monitor for the HAVEN 1 (emicizumab) study.

Dr. Kim previously was an assistant professor at the University of California, San Francisco, where he cared for adolescent and adult persons with hemophilia in the hemophilia treatment center.  In 2013, he received the Dr. Marion Koerper Award for Medical Excellence from the Hemophilia Foundation of Northern California.  He completed his clinical training in hematology/oncology at the University of California, Los Angeles; earned a master’s degree in policy analysis at the Pardee RAND Graduate School; and finished his undergraduate, medical school, and internal medicine residency training at Northwestern University.

BRIAN

O’MAHONY

BRIAN O’MAHONY

Brian O’Mahony is the Chief Executive of the Irish Haemophilia Society,  President of the European Haemophilia Consortium and former President of the World Federation of Hemophilia. He is a Fellow of the Institute of Biomedical Sciences (UK) and a Fellow of the Academy of Clinical Science and Laboratory Medicine (Ireland )and an assistant adjunct Professor in Health Service Management in Trinity College, Dublin. Brian O’Mahony has severe Haemophilia B.

JIM

HUNTINGTON

JIM HUNTINGTON

Jim Huntington graduated in 1989 from the University of Kansas with bachelor’s degrees in chemistry and mathematics. While an undergraduate, he worked as a research assistant in the Pharmaceutical Chemistry Department and at the Merck subsidiary InterX conducting chemical synthesis and in vitro and in vivo testing of prodrugs and prodrug-like enhancers of skin permeability. After graduating, he worked as a chemist at Alza Corporation in California for three years evaluating compounds that enhanced the electrotransport of drugs across the skin. He obtained a PhD from Vanderbilt University in 1997 for work on the biophysical characterisation of members of the serpin family of proteins with Peter Gettins. His research on the serpins continued during a postdoc with Robin Carrell at the University of Cambridge, where he used X-ray crystallography to determine the mechanisms of serpin function. He was appointed principal investigator at the Cambridge Institute for Medical Research in 1999, University Reader in 2007 and Professor of Molecular Haemostasis in 2011. His current research focuses on determining the structures of the molecular engines of blood coagulation, the Xase and prothrombinase complexes, using crystallography and single particle cryo-EM. Over the last four years he has founded several biotech companies, including: XO1 (acquired by Janssen Pharmaceuticals in 2015), SuperX and ReBalance in the field of thrombosis; ApcinteX in haemophilia; Z Factor to treat alpha-1-antitrypsin deficiency; and a reagents company, Cambridge ProteinWorks. He is CEO of ApcinteX and Visiting Professor at LaTrobe University.

JOHANNES

OLDENBURG

JOHANNES OLDENBURG

Professor Johannes Oldenburg, MD, is currently Director of the Institute of Experimental Haematology and Transfusion Medicine and of the Haemophilia Center, University Clinic Bonn. After receiving his medical degree, he has acquired numerous postdoctoral lecture qualifications, as well as qualifying as a specialist of transfusion medicine, and medical genetics.
Since 1995, Johannes Oldenburg’s research has been focused on the molecular genetics of blood coagulation factors, with a focus on hemophilia, and the vitamin K pathway (discovery of VKORC1, the target of cumarins). Johannes Oldenburg is author of more than 300 publications in these fields.
Johannes Oldenburg has received numerous scientific awards. He is a reviewer for most journals in the field of hemostasis, sits on the editorial boards for several high-impact journals, and is a member of directory boards for various associations.

JONATHAN 

GIBBINS

JONATHAN GIBBINS

Jonathan Gibbins gained his PhD in molecular endocrinology in under the mentorship of Prof Phil Lowry, where he gained an interest in cell signalling, a field that at that time was expanding rapidly.  He then moved to the laboratory of Prof Steve Watson, then in Oxford, to pursue this interest where he was introduced to the study of platelets and the regulation of their function.  His work with Steve was instrumental in establishing GPVI as the collagen receptor on platelets that regulates platelet activation, and initial steps in signalling pathways that this controls.  In 1998 Jon moved to the University of Reading to establish his own research group.  His work has led to the characterisation of inhibitory immune-receptor signalling mediated suppression of platelet function, and the discovery of the role of secreted chaperone proteins in the modulation of platelet receptor function.  He discovered a critical role for gap junction mediated intercellular signalling in the process of platelet thrombus formation, and the ability of a range in intracellular receptors to control platelet function through non-genomic mechanisms.  His work blends cell and molecular studies with the use of animal models of disease, and clinical studies.  Jon is Professor of Cell Biology at the University of Reading where he is also director of the Institute for Cardiovascular and Metabolic Research.

MARKUS

RIEDERER

MARKUS RIEDERER

Markus A. Riederer, Ph.D, Head DD Biologhy, at Idorsia Pharmaceuticals Ltd. Switzerland.
After completion of my doctoral thesis at the University of Basel, Switzerland, I continued my scientific education with a postdoctoral fellowship at Stanford University, School of Medicine, Stanford, CA, USA.
My career in drug discovery started in the Thrombosis Group at Hoffmann-La Roche, Switzerland with research on the fibrinogen receptor GP IIb-IIIa.  Subsequently, as a Project Leader of the “Novel Oral Anticoagulant Project”, my focus was shifted to the TF/F.VIIa coagulation pathway. In my new role as group leader in Actelion Pharmaceuticals Ltd. leading me into my current position, my scientific focus shifted back to platelet biology with the goal to discover and profile a novel P2Y12 antagonist.

GARY

MOORE

GARY MOORE

Gary Moore is the Consultant Scientist for the Diagnostic Haemostasis and Thrombosis Laboratories of Viapath Analytics at Guy’s and St. Thomas’ Hospitals, London, UK. Prior to his current role, he trained in diagnostic haematology at the Hospital for Sick Children at Great Ormond Street, spent seven years at the Royal London Hospital, and then took charge of the Bart’s coagulation laboratories for three years. He joined Guy’s & St. Thomas’ Hospitals in 1997 as a Chief and later a Principal Biomedical Scientist, becoming a consultant scientist in 2008. He received his doctorate in Biomedical Science from the University of Portsmouth in 2003 for a thesis on lupus anticoagulant detection. Dr Moore is Chief Examiner in Haematology for the Institute of Biomedical Science in the UK and member of their scientific advisory panel for haematology. He is also a visiting specialist lecturer at the universities of Kingston, Westminster, Middlesex and Portsmouth, and doctoral examiner for the latter.

Dr Moore’s main areas of interest and research are detection of antiphospholipid antibodies, thrombophilia testing, and diagnostic applications of snake venoms. He is a member of the ISTH SSCs for lupus anticoagulant/antiphospholipid antibodies and plasma coagulation inhibitors. He has published numerous papers on laboratory haemostasis/thrombosis diagnostics, published two text books, co-authored guidelines and is a regular peer reviewer for various haemostasis-related journals. He is also a regular presenter at national and international meetings.

WILLEM

LIJFERING

WILLEM LIJFERING

Willem Lijfering is a clinical epidemiologist at the LUMC, the Netherlands whose research focuses on the concept that that venous thrombosis and arterial cardiovascular disease are two different sides of the same coin. His research further includes the pharmacoepidemiology of anticoagulant drugs to the risk of thrombosis and major bleeding.

MARTINE

JANDROT-PERRUS

MARTINE JANDROT-PERRUS

Martine Jandrot-Perrus has devoted her research to understanding the mechanisms leading to the formation of a clot (physiological) / thrombus (pathological), with a particular interest for the processes taking place at the interface between the plasma (coagulation), the cells (platelets) and fibrin (fibrinolysis). She has largely contributed to the characterization of a major platelet receptor, glycoprotein VI (GPVI) with as major outcome the proposal that thrombosis is not a simple inappropriate haemostatic response but has specificities representing pharmacological targets to design antithrombotic molecules without haemorrhagic risk. Her work, having shown the remarkable inhibitory effect of the antibody fragment Fab 9O12 on GPVI functions, led to the development of therapeutic humanized Fab, ACT017. Data from preclinical studies and from first in human administration confirm that ACT017 combines safety (absence of bleeding) and antithrombotic efficiency.